Valuation: Cerus Corporation

Market Cap 524M 461M 434M 396M 741M 50.27B 748M 5.19B 2.01B 25.61B 1.97B 1.92B 83.2B P/E 2026 *
-74.6x
P/E 2027 * -261x
Enterprise Value 529M 465M 438M 400M 748M 50.75B 755M 5.24B 2.03B 25.85B 1.99B 1.94B 84B EV / Sales 2026 *
2.12x
EV / Sales 2027 * 1.88x
Free-Float
96.39%
Yield 2026 *
-
Yield 2027 * -
1 day+0.38%
1 week+3.16%
Current month-1.14%
1 month-7.12%
3 months+0.77%
6 months+43.41%
Current year+26.70%
1 week 2.52
Extreme 2.515
2.69
1 month 2.45
Extreme 2.45
2.79
Current year 1.62
Extreme 1.62
3.47
1 year 1.38
Extreme 1.38
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 2026-06-30
Chief Tech/Sci/R&D Officer 82 2015-06-30
Director of Finance/CFO 54 2009-05-03
Director TitleAgeSince
Chairman 59 2026-03-15
Director/Board Member 72 2014-03-23
Director/Board Member 51 2026-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

General Counsel

-30,000 0.0150%
7/16/26 Sell

Chief Executive Officer

-16,666 0.0083%
7/1/26 Free

Chief Executive Officer

924,215 0.4613%
Change 5-day change 1-year change 3-year change Capi.($)
+0.38%+3.16%+63.12%+74.00% 524M
-1.34%-5.27%-27.78%-5.44% 105B
-0.30%-3.60%-25.48%-3.27% 11.24B
+0.91%-5.25%+82.88%+105.74% 9.05B
-1.29%+3.85%-48.74%-66.54% 4.2B
-0.91%+6.88%-21.15%+29.07% 2.51B
-0.36%-5.42%-10.68%-62.81% 2B
-3.28%+6.48% - - 2.01B
-1.43%+0.79%-19.92%-27.50% 1.55B
Average -0.59%-0.60%-0.97%+5.41% 15.33B
Weighted average by Cap. +0.67%-3.54%-20.06%+0.10%

Financials

2026 *2027 *
Net sales 249M 219M 206M 188M 352M 23.9B 355M 2.47B 958M 12.17B 935M 915M 39.55B 272M 239M 225M 205M 384M 26.05B 387M 2.69B 1.04B 13.27B 1.02B 997M 43.12B
Net income -8.77M -7.71M -7.26M -6.63M -12.4M -841M -12.51M -86.91M -33.71M -428M -32.92M -32.2M -1.39B -1.67M -1.47M -1.38M -1.26M -2.36M -160M -2.38M -16.52M -6.41M -81.46M -6.26M -6.12M -265M
Net Debt 5M 4.4M 4.14M 3.78M 7.07M 480M 7.13M 49.57M 19.22M 244M 18.77M 18.36M 794M -13M -11.43M -10.76M -9.84M -18.38M -1.25B -18.55M -129M -49.98M -635M -48.81M -47.75M -2.06B
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
26-09-24 US$2.610 +0.38% 1,819,594
26-09-23 US$2.600 -2.62% 1,635,868
26-09-22 US$2.670 +4.30% 3,817,930
26-09-21 US$2.560 -3.40% 1,915,017
26-09-18 US$2.650 -0.38% 3,570,322
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.600USD
Average target price
5.125USD
Spread / Average Target
+97.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock